CXCL10 and neoplasm: Our data suggested that treatment of anti-PD-L1-IFN-α fusion protein is effective in an anti-PD-L1 resistant syngeneic mouse tumor model and the upregulation of IP-10 in the tumor microenvironment may contribute to the anti-tumor efficacy.